Skip to main content

Efinaconazole (Monograph)

Brand name: Jublia
Drug class: Azoles
ATC class: D01AC03
VA class: DE102
Chemical name: (αR,βR)-α-(2,4-Difluorophenyl)-β-methyl-4-methylene-α-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidineethanol
Molecular formula: C18H22F2N4O
CAS number: 164650-44-6


Antifungal; azole (triazole derivative).

Uses for Efinaconazole


Topical treatment of onychomycosis of the toenails (tinea unguium, ringworm of the nail) caused by Trichophyton rubrum or T. mentagrophytes.

Efinaconazole Dosage and Administration


Topical Administration

Apply 10% solution topically to affected toenails using flow-through brush applicator supplied by the manufacturer.

Do not administer orally or intravaginally; do not apply topically to eyes.

Clean and dry toenails prior to application; do not apply until ≥10 minutes after showering, bathing, or washing.

Using the integrated flow-through brush applicator supplied by the manufacturer on the bottle, place 1 drop of solution on each affected toenail. Use attached brush applicator to gently spread solution evenly over entire toenail surface, including cuticle, folds of skin next to sides of toenail, toenail bed, hyponychium (thickened epidermis underneath toenail tip), and undersurface of toenail tip. For the big toenail, apply second drop at the end of the toenail. Do not squeeze applicator bottle while spreading solution over toenails.

Allow solution to dry on the toenails.

Wash hands with soap and water after applying the drug.

Avoid pedicures and use of nail polish and other cosmetic nail products during efinaconazole treatment.




Apply 10% solution to affected toenails once daily for 48 weeks. Use amount sufficient to cover entire toenail surface and under toenail tip. (See Topical Administration under Dosage and Administration.)

Special Populations

No special population dosage recommendations.

Cautions for Efinaconazole



Sensitivity Reactions

May cause application site irritation (e.g., redness, swelling, burning, itching, blisters); no evidence that the drug causes contact sensitization.

Administration Precautions

For topical use only. Do not use orally or intravaginally; do not apply to eyes.

Selection and Use of Antifungals

Prior to treatment of onychomycosis, confirm diagnosis by direct microscopic examination of scrapings from infected toenails mounted in potassium hydroxide (KOH) or by culture.

Specific Populations


Category C.


Not known whether distributed into human milk following topical application; distributed into milk of rats after sub-Q administration. Use with caution in nursing women.

Pediatric Use

Safety and efficacy not established in pediatric patients.

Geriatric Use

No overall differences in safety and efficacy in older adults relative to younger adults observed in clinical trials, but greater sensitivity of some older individuals cannot be ruled out.

Common Adverse Effects

Application site dermatitis, ingrown toenail, application site vesicles, application site pain.

Drug Interactions

Does not inhibit CYP1A2, 2A6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4 and does not induce CYP1A2 or 3A4 in vitro at concentrations expected clinically.

No formal drug interaction studies to date. Clinically important interactions with CYP inhibitors or inducers unlikely because systemic exposure is low following topical application of efinaconazole to toenails.

Efinaconazole Pharmacokinetics



Following topical application of efinaconazole 10% solution to toenails, low concentrations are absorbed systemically.

Mean peak plasma concentration was 0.67 ng/mL after 28 consecutive days of once-daily topical administration of the 10% solution to all 10 toenails and up to 0.5 cm of skin surrounding each toenail. Plasma concentrations of the drug still detectable in some patients 2 weeks after last dose.

Steady-state concentrations achieved after about 14 days of once-daily topical application.



Following systemic absorption, efinaconazole undergoes oxidative metabolism via multiple CYP isoenzymes, principally CYP2C19 and 3A4. Major metabolite (H3) is inactive.


Plasma half-life of 29.9 hours reported following 7 consecutive days of once-daily topical application to all 10 toenails in a study in healthy adults.





20–25°C (may be exposed to 15–30°C). Do not freeze.

The 10% solution contains alcohol and is flammable; do not store or use near heat or open flame.

Keep bottle tightly closed.

Actions and Spectrum

Advice to Patients


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.



Dosage Forms


Brand Names







AHFS DI Essentials™. © Copyright 2024, Selected Revisions February 13, 2015. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

Reload page with references included